In the realm of BOTOX battles, there is still no clear winner. Merz Aesthetics, a division of Merz North America, recently announced positive results from a clinical trial designed to evaluate the efficacy of Xeomin® (incobotulinumtoxinA) in the treatment of glabellar lines, when compared to BOTOX® Cosmetic (onabotulinumtoxinA).
It may sound like comparing Coke to Pepsi to most of us, who are more interested in which of the FDA approved pretty poisons (There are 3 of them currently – Botox, Xeomin and Dysport) will smooth our foreheads and crow’s feet best. The answer, we have learned, is at least between Botox and Xeomin, it’s kind of a draw.
According to Michael H. Gold, M.D., Medical Director of Gold Skin Care Center in Nashville, TN, a key clinical investigator in the study, “In this head to head randomized double blinded study of Xeomin to BOTOX Cosmetic in the glabellar frown lines, we found that both treatments worked in reducing the wrinkles in the glabellar area – all primary endpoints of wrinkle reduction were met with both medicines through four months of evaluations. Therefore, physicians can have options when using toxins for injections, and not be afraid that one product may be inferior to another, based on this clinical evaluation.”
This is certainly good news for anyone with a furrowed brow in search of a solution. Based on this extensive multicenter clinical trial, Xeomin was shown to be safe and effective, having been approved by the FDA in 2011 for improvement in the appearance of moderate-to-severe glabellar frown lines. Although so far, it is only indicated for the wrinkles that form between your brows, your dermatologist or plastic surgeon may use Xeomin in other areas of the face, such as crow’s feet, forehead lines, upper lip lines, neck muscle bands, and more.
There is more than one option for stopping dynamic wrinkles in their tracks. Find an experienced Xeomin practitioner near you at xeominaesthetic.com